Elevated lncRNA XIST expression predicts poor OS, poor disease free survival (DFS), larger tumor size, increased distant metastasis and advanced tumor stage in esophageal squamous cell carcinoma, pancreatic cancer, colorectal cancer, gastric cancer, nasopharyngeal carcinoma, non-small cell lung cancer (Zhu et al., 2018) and hepatocellular carcinoma (Ma et al., 2017). This evidence concerns the gene XIST and nasopharyngeal carcinoma.